Clinicians should use a neuraminidase inhibitor, preferably oseltamivir, as first-line treatment for patients with H5N1 avian influenza but should also consider using an older class of antiviral drugs under certain circumstances, according to new guidelines issued on May 19 by the WHO (http://www.who.int/medicines/publications/WHO_PSM_PAR_2006.6.pdf). The guidelines were developed by an international group of experts, including clinicians with experience treating patients with the infection.
Stephenson J. Older Drugs for Avian Flu. JAMA. 2006;295(23):2711. doi:10.1001/jama.295.23.2711-c